wow, this below quote is from the UK Medicines Information site…they are tied into the National Health Service (NHS).which is proposing a possible "approval trial" of TB 4 in Dry Eye. The KEY point is that they know all about the Phs 2 Ora Inc did in US. Recall that ALL investors & Pharma firms, in the US, believe that trial flopped. The endpoint was only in one tiny SUBSECTION of the cornea, where TB 4 did not get "statistical" efficacy. Howver the NHS in England (actually the N.I.C.E) does not CARE about the tiny 25% sub section with not statistical good results….they only seem to care about the rest of the 75% of all the cornea, where TB 4 was with statistical efficacy….and any of THESE markers would have gotten our FDA approval. Read exactly what the UK websites said of TB 4 and why they want to possibly try it in an approval trial. RGRX management is hiding this from investors. It is public knowledge if you just look on the web.
They dont seem to care where TB 4 didn't work as well, in a tiny subsection area……England cares where TB 4 worked in 75% of the REST of the cornea.
If you were bidding 13 cents and NITE showed an offer of 5,000 at 13 cents….you should have been filled on that..otherwise NITE is just scamming.
if you want to set computer whistles off…..bid for stock at 13.2 cents….if NITE is still offering on the ask 5,000 at 13 cents even…..and won't fill …. That would get some attention..offered at 13 cents, bid at 13.2 cents.
Short warrants and buy stock. I'd short the warrants for 10 cents…….then buy stock at 13 or 14 cents. Good trade. Max loss 3.5 cents…..Max win about 53 cents.
I wasn't paying much attention to level2…doing other places. But if you saw what you say you saw, interesting. Quote:
So as the bidder moves up in size to just below NITES offer…NITE actually SHORTEd into that bid? So NITE was shorting on the DOWNTICK bid? NITE wasn't just shorting with seeing their OFFER takeen out….if it would ever get taken out?
There's a big difference there…a market maker puts "offers" out on the "ASK" side of the trade…..short or long…as what they do to "make a market".…they just wait and see if it get's taken out. But it is a DIFFERENT trade if NITE sees the bidder come up closer to their "ask"….and NITE willingly chooses to ….and short into that, on a DOWNTICK. What that tells you is that NITE isn't shorting as a MM…..leaving short offer on the "ask"….but that NITE is position trading RGRX short - by shorting INTO a downtick print. That is a position trade "short"…….shorting on the "offer" is a market making short. SEC regulations supposedly are strict on that. MArket Makers cannot use market maker advantages for a POSITION trade. They only get MM advantages for trading in the "ordinary course of business". IMO? NITE has been cheating for years here….with a large POSITION trade short in RGRX that is so large it has nothing to do with "ordinary course of business" of buy/sell/buy/sell. Which means they don't have to borrow stock, if short, and they don't report the short trade to SEC. It's naked shorting basically, legal. 65k shorted today alone. The SEC thinks there is TOTAL 6.000 shoprt in RGRX. Joke.
Hows that. 65,000 RGRX traded short today…that is 65^ of ALL volume. NITE is not giving up. Lucky for them the "value" of the 100,000 shares traded is a pittance…but if it's such a pittance, then why do they try so hard to "cap" RGRX from going up? why don't they let it run up with these retail buyers..…say, 16 or 17 cents…and THEn short it down. NITE doesn't read boards. All they know how to do is short the whole basket of tiny spec bios thaty make a market in. But seeing how aggressive they are to keep RGRX down.what are they worried about? NITE can put up trades and prints anyway they want. They don't have to borrow stock if they are short… they don't have to report their short position to SEC. They can short on a downtick, or an uptick..anytime they please. So why are they so hell bent on not letting RGRX over13 cents..and will short 65% of the total days volume to do so.
IMO? They have a very large short position, unreported to SEC (legally, sort of)……and they are betting that "retail" is wrong…and that RGRX is going bust sooner than later.
another dopey post. The pickup in volume in last few weeks of December had nothing to do with the Cavazzas consolidating their RGRX family holdings on Dec 5…the volume increase was simply due to tax loss selling….and the MM's were expecting it..and they brought down the bids in anticipation of that volume…..and the volume of sell shares were long tax losses….and the MM on the buy side was probably covering the shorts they have had for a long time.
Cavazzas didn't buy any. They would have had to file w/ SEC within three business days if they bought (or sold) a share. So no conspiracy theory there.
hey, I don't mind were're at almost 13 cents. better than the tax loss puke down to 5 cents….but I can't get excited, as some do…..100,000 shares in a day for volume sounds really cool to some. But the reality is that 100,000 shares is worth a grand total of $13,000. Which, I hate to tell you again…is all retail. if you want to go much higher, you'll need to see some real money coming down….not $13,000 a day in TOTAL value traded.
Is there a school you attended to get a degree in trying to sound ohhh so smart, but stupid? You jump on what I stated as that the players now in RGRX are 'wishful retail" people. You say I can't see the tape? You keep harping on some hidden and deliberative conspiracy theory? Lemme spell it out for you real clear….obviously your "school" didn't teach you this. Yesterday, 124,000 shares of RGRX traded. We'll call teh average price was 12 cents a shares. Multiple 124,000 shares times 12 cents. The GRAND TOTAL VALUE of ALL RGRX shares traded yesterday was…$14,880.
So yes…..when the TOTAL days value of shares traded is $14,880..I'll teach YOU a lesson..it is a "retail" group that is here…..not an institutional one…….and there is no conspiracy..here or in German trading RGRX. The only thing that comes close to a conspiracy is that NITE is always shorting RGRX. NITE is not singling out RGRX. NITE probably makes a market in 200 such tiny spec bioyechs as RGRX….and they play the short side hard in ever one, I bet. And they will probably lose on a handful…..but make good money on every other one they are short. As a group trade shorting, tiny speculative, under financed bios….with no institutional support….makes them dough. Short.
There is no hidden conspiracy to keep RGRX down..so as to buy on the cheap. There are no institutions interested in investing in RGRX. RGRX is 100% a "retail wishful thinking lottery ticket trade".. (that does include myself) Proof of that is yesterday total vale traded was $14,880.
Do you really have to post nonsense in reply ?
out if 124,00 traded today, 47,000 was short traded. That's just under 40% of volume. NITE must be getting frustrated….capping us. The buyers are wishful retail folks…so we're no match for whatever they want to do..price wise.NITE is prety much in contril here..and they have been for quite a while. Retial buyers will never be able to "volume up" RGRX.…much above where it is now..without news.…and the news has to be good and worthy. We here know that England's National Health Service is considering an approval trial for TB 4 in dry eye. We know it because I've posted the facts of it. RGRX mgmt reads this board, so they know..that we know…but they still stay silent. I don't know if this is the news they wait for. It might not be. Because the latest $40,000 "band aid" will only last till mid to late February. Then RGRX is bust - yet again. And even if they announce that England's NHS will do an approbal trial..no cost to RGRX (save providing TB 4 free)….it could take up to a year to do. Becaus they won't have a CRO like ORA Inc to execute quickly…SO??? Are there other things they wait on - besides the British NHS (hidden)? In meantime…NITE will do what they want.
I would be leery of leaving a couple orders to fill Good Till Canceled at lower prices. There's always a chance that there is bad news, and your orders would fill at a not so good time. If you want to bid below, I'd just enter them as day orders.
It's possible you'll see 10 cents. but who knows. If NITE has their way they'll get it to a 10 cent print….but will there be other bidders ahead of you? or, what if RGRX does put good news out sooner, rather than later? Then you might kick yourself for not buying 12 cents shares, but missed because you wanted only 10 cent shares..… 10,000 shares at 12 cents is $1,200. 10,000 shares at 10 cents is $1,000……it's only a $200 difference,..on 10,000 shares…..if $200 is that critical and important to you….then be careful ever being in things like RGRX to begin with. But if you think there's a chance that TB 4 will get an approval somewhere or a good partner deal….you won't have any chance to buy at this range. At least you know what your risk is if you lose….12 cents. Who knows the upside. I don't. We need the stuff the mgmt keeps to themselves.
that is more evidence that the MM(s) are short far more than reported 6,000 shares or so to the SEC. Try a couple million at least (imo) The MM (NITE?) can do what they want and put up prints when they want…even printing a last trade one cent below the legitimate bid…so they can "mark" RGRX down so their position (short, a lot) closes favorably - for a day….then do it again next trading day.and next..…..as long as it takes to keep it down. This has worked fabulously well for NITE for years now and they have been right. They've made money….we lost money. Only way it will change is if we get significant good news very soon…or?….we somehow snag a buyer who wants to play the gamble and buy a couple million shares. But that is unlikely until RGRX shows something newsworthy wise, to get someones speculative juices going. Seeing how that RGRX hid the Neuro granted patent from us for one month (given Dec 23)….and RGRX did NOT disclose the FDA given Orphan status - until it was caught by others on the FDA wire - only then RGRX did tell us, after the fact…and seeing how RGRX is now hiding from investors (not us) the potential big news of a British NHS approval trial for TB 4 in dry eye…WELL? No big buyer will come. It's only us retail, against the likes of NITE. And we can't beat them.
In theory you are right. If you place a GTC sell order at a price above, then technically your stock can't be borrowed against a short sale.
Your thought is noble, but I wouldn't waste the time or effort. I figure there's about 80 million RGRX shares out. You, taking your shares off a short borrow list won't matter. Furthermore, the shorts in RGRX are not hedge funders or retail people….it is MARKET MAKERS. And mostly it's NITE.
Market Makers are exempt from regulation that they have to borrow shares each time they short..and market makers are exempt from telling the SEC that they are short. That is why the SEC believes there is only about 6,000 shares short in RGRX.The MM's do not report. I figure the MM (s) are short between 2-3 million RGRX. So, if there are about 80 million shares out….that leaves about 77 million shares out there to borrow. If you take your shares of the short stock borrow list….it won't make a difference.. Market makers don't have to borrow shares anyways…..and it is the MM's who are the short players here.
Wow. Shire Pharma in 2011 paid $750 MILLION for a skin & ulcer therapy. Amazing thing was they paid $750 million and it had NOT gotten FDA approval. Soon after Shire bought it, the FDA rejected. Shire today sold the therapy for a $650 million loss. On a cost and risk reward basis….TB 4 is a far better buy for a pharma. HAd RGRX not signed on pts with stage 3 & 4 ulcers (basically incurable)…TB 4 may have world, on stage 1 & 2 ulcers. Shire paid $750 MILLION for an UNAPPROVED therapy. RGRX mkt cap about $8 million here. Buy for skin $ 8 mill, you get Neuro, Eyes and heart stuff for FREE:
"Irish pharmaceuticals company Shire (SHPG_) said on Friday it had arranged to hand its Dermagraft skin substitute to Organogenesis and take a $650 million loss on the disposal, which unwinds a major part of an acquisition it made less than three years ago. Dermagraft is used to treat the foot ulcers that often accompany diabetes. Shire acquired the treatment when it paid $750 million up front for VC-backed Advanced BioHealing, of Westport, Conn., in May 2011, preempting the target's initial public offering. But Dermagraft didn't live up to Shire's expectations, particularly after the treatment failed to get Food and Drug Administration approval for its use on leg ulcers just weeks after the Advanced BioHealing deal. "
when you see NITE putting a 50,000 or 100,00 share offer out there to "cap" RGRX price, you can darn sure bet that NITE is opening that offer as a short in RGRX. I highly doubt it is a long offer from NITE. I'd say anything NITE offers is a short sale. It would be great to see someone take those offers out and then see some kind of hoped for news to push it higher, then NITE is stuck. But I will say, for years now, selling short and offering size to sell, has played out well for NITE. Here's to hoping that someday might come back to hurt them.
NITE isn't going to give up their dreams of RGRX going bust anytime soon. 121,000 were traded short today, my bet is a good portion of that the NITE mm. That equals about 35% of all volume.
news is looking up, but we're not there yet. Neuro patent doesn't guarantee any one comes to partner it….but it is more attractivve with the IP locked up.
The bigger news that would frustrate NITE's shorting actions would be if RGRX would announce publically what is going on in England with the plans of an arm of their National Health Service, to do a less onerous approval trial (than our FDA in USA) for Dry Eye. It reads to me like that is what their NHS wants to try, and it reads to me like RGRX won't have to pay for it. ALl RGRX has to do is give them now what they would charge for TB 4…(and provide the TB 4)… if the tests the NHS do ever work out positively.
RGRX hid the fact that we got the Neuro patent - on Dec 23, 2013…a months ago. RGRX did not disclose that they got FDA Orphan designtation in eye area NK….until it hit wires on the internet. And RGRX mgmt is doing it again, hiding from shareholders a possible major deal that they have in the works with England's NHS. Is our management on the side of short seller MM NITE? Or us?
The two neuro areas that would interest a pharma partner the most….are these two….and RGRX was granted Patent of TB 4 in them:
"…. Alzheimer's disease, multiple sclerosis (MS)….."
Huge amounts of research dollars go into these Alzheimers and MS…… TB 4 is now patent protected in Alzheimers and MS…….and TB 4 is a safe and side effect free drug. Biogen is a leader here…and they are worth billions and billions…why wouldn't they take a few million gamble on TB 4? The pre clinical work Henry Ford already has done..is not from a fly-by-night kind of place. Maybe Henry Ford will do a small physician sponsored phase 2….
After SIX rejections by the USPO, they finally gave in and granted it to RGRX. I was off a bit on original date filed. It was early 2006, not 2007….almost 8 years the USPO d*** around with RGRX. That's not right. And the USPO did the same thing with many, many other filings by us. Now that RGRX all but bankrupt, they grant them???
Here's what the patent covers in neuro. They removed coverage for Parkinson's and ALS.
"Neuro-degenerative diseases, muscular-degenerative diseases and neuro-muscular-degenerative diseases are debilitating diseases that can destroy memory, brain functions, muscle functions and other physiological functions of a subject. Such diseases may be genetic, or result from exposure by a subject to factors in the environment, contaminated food, and the like. Such diseases may include Alzheimer's disease, multiple sclerosis (MS), spinal muscular atrophy (SMA), myasthenia gravis, autism, muscular dystrophy, transmissible spongiform encephalopathies (TSEs) including bovine spongiform encephalopathy (BSE), and the like. "
I found the TB 4 patent app for neuro. It is slightly different than the one Henry Ford filed, but Henry Ford was rejected. If you care to read at USPO, the RGRX Neuro patent publication no# is 20080274098. It was HELl for RGRX. They filed it on July 2, 2007. From 2007 to 2013, the USPO sent FIVE….count FIVE.."non final rejection" notices. Then on July 1, 2013…the USPO had had enough and they sent RGRX a 'FINAL REJECTION" notice……that being the SIXTH rejection. But then a strange thing happened. Dec 12, 2013 a phone call comes…then, after SIX rejections and after a phone call…the patent examine (a b***h lady who has screwed w/ RGRX many years, many times).changes her MIND after a phone call! Then on Dec 23, 2013, the USPO notified RGRX that the Neuro patent is granted.
I read the docs..and after that phone call and SIX rejections, all the papent lady did was say to remove two areas of therapy…..remove it for ALS and Parkinson's Disease. if RGRX removed those two areas, she would grant the patent TB 4 for all other neuro areas. Something odd hapenned at the patent office. This lady f**** RGRX for 7 years… and longer on numerous RGRX filings. But something or someone got to her…. somehow.
The second thing that is TYPICAL hiding news by RGRX.…in that they were notified on Dec 23, 2013 that they got the neuro patent. It is now January 16…so RGRX chose to hide and not disclose this to shareholders - for almost ONE MONTH. Just like RGRX tried to hide the FDA Orphan Status news…and just like NOW.…RGRX is hiding major, major possible trial news from the British Health Service.
But we got the Neuro patent, so we have IP to offer if any pharma wants to try it. Who knows if they will.
….In the latest study, adult rats were dosed with Thymosin beta 4 one day after they were subjected to a blockage in the cerebral artery, then given four more doses, once every three days. Rats treated only with saline were used as a control group.
After eight weeks, the Thymosin beta 4 group showed significant overall improvement compared to the control group. The researchers concluded that the peptide improved blood vessel density as well as promoted a certain type of immature brain cells called oligodendrocyte progenitor cells to differentiate into mature oligodendrocytes,
The researchers concluded that the peptide improved blood vessel density as well as promoted a certain type of immature brain cells called oligodendrocyte progenitor cells to differentiate into mature oligodendrocytes, which produces myelin to protect axons in nerve cells.
In addition to Dr. Morris, the Henry Ford research team included Michael Chopp, Ph.D.; Li Zhang, M.D.; and Zheng Gang Zhang.
Thymosin beta 4 is produced by RegeneRx Biopharmaceuticals, Inc.